Fax: (301) 480-3929
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials †‡
Article first published online: 20 DEC 2012
DOI: 10.1002/cncr.27916
Copyright © 2012 American Cancer Society
Additional Information
How to Cite
Lee, J.-m., Hays, J. L., Noonan, A. M., Squires, J., Minasian, L., Annunziata, C., Wood, B. J., Yu, M., Calvo, K. R., Houston, N., Azad, N. and Kohn, E. C. (2013), Feasibility and safety of sequential research-related tumor core biopsies in clinical trials . Cancer, 119: 1357–1364. doi: 10.1002/cncr.27916
- †
This article is US government work and, as such, is in the public domain in the United States of America.
- ‡
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
- §
Fax: (301) 480-3929
Publication History
- Issue published online: 18 MAR 2013
- Article first published online: 20 DEC 2012
- Manuscript Accepted: 1 NOV 2012
- Manuscript Revised: 5 OCT 2012
- Manuscript Received: 3 AUG 2012
Funded by
- Unknown funding agency
REFERENCES
- 1, , , . Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000; 18: 684-692.
- 2. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007; 357: 39-51.
- 3, , , et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
- 4, , , . Proteomics and biomarkers in clinical trials for drug development. J Proteomics. 2011; 74: 2632-2641.
- 5, , , et al. Modeling pharmacodynamic response to the poly(ADP-ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells [serial online]. PLoS One. 2011; 6: e26152.
- 6, , , . Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005; 23: 2020-2027.
- 7US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed November 20, 2012.
- 8, , , et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007; 110: 309-317.
- 9, , , et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007; 109: 1323-1330.
- 10, , , et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res. 2010; 16: 664-672.
- 11, , , et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008; 26: 3709-3714.
- 12
- 13. Laparoscopic pelvic lymphadenectomy in obese women with gynecologic malignancies. J Am Assoc Gynecol Laparosc. 1995; 2: 163-167.
- 14, , , . Hysterectomy for obese women with endometrial cancer: laparoscopy or laparotomy? Gynecol Oncol. 2000; 78: 329-335.
- 15. Laparoscopy in the massively obese female. Obstet Gynecol. 1987; 69: 423-424.
- 16, , , et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res. 2001; 7: 2971-2976.
- 17, , , , . Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J Clin Oncol. 2008; 26: 3987-3994.
- 18, , , et al. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience. Oncologist. 2011; 16: 1292-1298.
- 19, , , et al. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Ann Oncol. 2012; 23: 1301-1306.
- 20, , , et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010; 28: 2635-2640.
- 21, , , . Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol. 2006; 24: 4801-4807.
- 22, , . Percutaneous CT-guided multisampling core needle biopsy of thoracic lesions. AJR Am J Roentgenol. 2005; 185: 1294-1298.